Skip to content

Study · Systematic review · 2026

4 results

GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles.

Li Y, Xu X, Tuersun A, Fan X, Qin M, Zhao X, Abuduaini S, Xing H, Chen H

Pharmacological research4 Jul 2026

PMID42401410 (opens in a new tab)DOI10.1016/j.phrs.2026.108333 (opens in a new tab)PepBankPUB-42401410
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adolescents with overweight or obesity, semaglutide 2.4 mg SC was associated with the largest body weight reduction among agents (mean difference -18.00 kg).

    In plain wordsIn adolescents with overweight or obesity, pooled trials linked semaglutide 2.4 mg to the largest weight loss among the drugs compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight mean difference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Body weight mean difference
    −18 kg
    semaglutide 2.4 mg SC

    Source sentences

    Summary
    Semaglutide 2.4 mg SC was associated with the largest reductions in body weight (mean difference -18.00 kg; 95% credible interval -24.34 to -11.69, high confidence
    2 context sentences
    Summary · context
    Randomised clinical trials comparing GLP-1RAs with placebo or another active agent in eligible adolescents were included.
    Summary · context
    17 RCTs with 1230 participants were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adolescents with overweight or obesity, semaglutide 2.4 mg SC was associated with the largest BMI reduction among agents (-5.9 kg/m2).

    In plain wordsIn adolescents with overweight or obesity, pooled trials linked semaglutide 2.4 mg to the largest BMI reduction among the drugs compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI mean difference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    BMI mean difference
    −5.9 kg/m2
    semaglutide 2.4 mg SC

    Source sentences

    Summary
    Semaglutide 2.4 mg SC was associated with the largest reductions in body weight (mean difference -18.00 kg; 95% credible interval -24.34 to -11.69, high confidence), BMI (-5.9 kg/m2, -10.5 to -1.3, high confidence
    2 context sentences
    Summary · context
    Randomised clinical trials comparing GLP-1RAs with placebo or another active agent in eligible adolescents were included.
    Summary · context
    17 RCTs with 1230 participants were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adolescents with overweight or obesity, semaglutide 2.4 mg SC was associated with the largest waist circumference reduction among agents (-12.2 cm).

    In plain wordsIn adolescents with overweight or obesity, pooled trials linked semaglutide 2.4 mg to the largest waist reduction among the drugs compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference mean difference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Waist circumference mean difference
    −12.2 cm
    semaglutide 2.4 mg SC

    Source sentences

    Summary
    Semaglutide 2.4 mg SC was associated with the largest reductions in body weight (mean difference -18.00 kg; 95% credible interval -24.34 to -11.69, high confidence), BMI (-5.9 kg/m2, -10.5 to -1.3, high confidence), and waist circumference (-12.2 cm, -21.67 to -2.67)
    2 context sentences
    Summary · context
    Randomised clinical trials comparing GLP-1RAs with placebo or another active agent in eligible adolescents were included.
    Summary · context
    17 RCTs with 1230 participants were included.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a network meta-analysis in adolescents with overweight or obesity, no GLP-1 receptor agonist improved lipid profiles in a statistically significant manner.

    In plain wordsIn a pooled analysis of trials in adolescents with overweight or obesity, none of the GLP-1 drugs clearly improved blood fats.

    Peptide
    Semaglutide
    Outcome
    No significant changeLipid profiles across all GLP-1RAs
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    No agent improved lipid profiles in a statistically significant manner.
    2 context sentences
    Summary · context
    Randomised clinical trials comparing GLP-1RAs with placebo or another active agent in eligible adolescents were included.
    Summary · context
    17 RCTs with 1230 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    11 Oct 2026, 00:04 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.